Panacea Biotec Shares Soar 9% on Phase III Trial for DengiALL
January 8, 2026January 8, 2026 Shares of Panacea Biotec Ltd soared 9% on 8 January after the company announced that enrollment in the Phase III clinical trial of DengiALL, its tetravalent dengue vaccine candidate, had been completed. DengiALL is a single-dose vaccine that protects against all four strains of…